From: Improving the analysis of composite endpoints in rare disease trials
Disease | Example responder endpoint |
---|---|
Primary biliary cholongitis (PBC) | ∙ ALP <1.67×ULN |
∙ Total bilirubin < ULN | |
∙ ALP decrease ≥ 15% | |
Behçets disease | ∙ Length of principal intestinal |
ulcer compared to size at baseline (%) | |
∙ No new lesions | |
Lupus Nephritis | ∙ eGFR no more than 10% below |
preflare value or normal | |
∙ Proteinuria UPC ratio < 0.5 | |
∙Urine sediment: Inactive | |
∙ No rescue therapy | |
Neuroblastoma | ∙ < 10mm residual soft tissue at |
primary site | |
∙ Complete resolution of MIBG of | |
FDG-PET uptake (for MIBG non avid | |
tumours) at primary site | |
Advanced hepatocellular carcinoma | ∙ < 20% increase in the sum of the |
longest diameters of target lesions | |
∙ No new lesions |